Bottom line
A marketed two-component research-peptide combination (BPC-157 + TB-500) sold under the "Wolverine" name. No published study of the exact marketed combination was identified, and separate component findings do not establish the behavior of the mixture.
The adjacent name "Wolverine Plus" is compositionally ambiguous: observed listings add either KPV or GHK-Cu. It should not be treated as a standardized extension of Wolverine.
No established or recommended human dose.
Name and formulation variability
| Observed source/date | Claimed components | Claimed amounts | Verification limits |
|---|---|---|---|
| Legion Peptides (2026) | BPC-157, TB-500 | 10 / 10 mg (20 mg total) | Vendor-declared; unverified purity claims |
| Oath Research batch 2604130351 (2026) | BPC-157, TB-500 | 5 / 5 mg; net content 6.11 / 4.85 mg | Vendor-supplied COA; unverified |
| Peptide.Express (2026) | BPC-157, TB-500 | Variable; sold as pre-blended vial or two-vial kit | Vendor-declared; unverified |
| Improved Peptides (2026) | BPC-157, TB-500 | Individual vials only (no pre-blend sold) | Vendor-declared; unverified |
| "Wolverine Plus" variants (2026) | BPC-157, TB-500, plus KPV or GHK-Cu | 10/10/10 mg, 25/10/10 mg, or unstated | Adjacent name with incompatible third components; vendor-declared only |
Also known as: Wolverine Stack, BPC-157/TB-500, BPC/TB Blend, Combo Vial: BPC-157/TB-500.
"Wolverine Plus" is documented separately at BPC-157 + TB-500 + KPV, with the GHK-Cu substitution recorded as a naming collision rather than a formulation equivalent.
The most common observed commercial formulation is a 1:1 mass claim (5/5 or 10/10 mg). This is a market observation, not guidance or evidence that the ratio is standardized. TB-500 identity ambiguity also prevents a mass label from resolving a consistent molar composition.
Component evidence
| Component | Separate evidence | Evidence for combination | Compatibility/stability evidence |
|---|---|---|---|
| BPC-157 | See component monograph; it does not establish performance of this mixture | None identified for the marketed combination | No published co-formulation stability data identified |
| TB-500 | See component monograph; identity ambiguity is material | None identified for the marketed combination | No published co-formulation stability data identified |
Combination-specific studies
No published peer-reviewed study was identified that evaluates the exact marketed BPC-157 + TB-500 mixture against its individual components or a control. Seller claims about the combination are market observations, not evidence.
Safety and interaction uncertainties
Any adverse event cannot be attributed to one component in a pre-blended vial
The fixed ratio prevents independent dose adjustment
TB-500 molecular-weight ambiguity (43-AA vs 7-AA fragment) means label claims may not reflect actual molar ratios
No human safety data for the combination exists
WADA: BPC-157 is listed under S0; thymosin-β4 and derivatives such as TB-500 are listed under S2.3. Both are prohibited at all times, but not under the same subsection.
Regulatory and product-quality notes
Wolverine and Wolverine Plus are market names, not regulatory or pharmacopoeial standards.
Regulatory status must be assessed for each exact component, product, indication, and jurisdiction.
"Research use only" and seller-supplied certificates do not establish approval, safety, sterility, authenticity, or suitability for humans.
Evidence gaps
No combination pharmacokinetic study
No dose-ratio optimisation study
No study with individual-component control arms
No evidence that separate component findings transfer to the marketed mixture
No long-term safety data
Sources
Aminocore Research. Wolverine Blend Analysis. https://aminocoreresearch.com/articles/wolverine-blend-bpc-157-tb-500 accessed 2026-08-06.
Peptide.Express. BPC-157 + TB-500 Wolverine Stack Guide. https://peptide.express/guides/bpc-157-tb-500-wolverine-research-guide accessed 2026-08-06.
Disclosed Labs. BPC-157 + TB-500 testing data. https://www.disclosedlabs.com/peptides/bpc-157-tb-500 accessed 2026-08-06.
Aminoscope. The BPC-157 + TB-500 blend. https://aminoscope.com/research/bpc-157-tb-500-blend accessed 2026-08-06.
Oath Research. "WOLVERINE" Certificate of Analysis. https://oathresearch.com/lab-results/wolverine-bpc-157-tb-500-batch-2604130351/ accessed 2026-08-06.
Improved Peptides. Wolverine Stack Research Profile. https://improvedpeptides.com/research/wolverine-stack/ accessed 2026-08-06.
World Anti-Doping Agency. 2026 Prohibited List. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
Peptide Plugs. Wolverine Plus product page. https://peptideplugs.com/product/wolverine_plus/ accessed 2026-08-08.
Protide Health. Coremend TB-500/BPC-157/KPV product page. https://protidehealth.com/product/coremend-tb500-bpc157-kpv accessed 2026-08-08.